


Peri-Op chemo						
At Risk	121	115	95	75	51	25
Events	0	4	18	23	28	30

TNT						
At Risk	28	25	17	10	3	1
Events	0	3	6	8	9	9



Peri-Op chemo						
At Risk	37	33	23	14	3	0
Events	0	4	11	12	13	13

TNT						
At Risk	22	15	7	3	0	0
Events	0	7	8	10	11	11

Figure S1 Kaplan-Meier analysis of overall survival (A) and recurrence-free survival (B) in TNT and perioperative patients who received FLOT chemotherapy.

Table S1 Baseline patient characteristics for TNT and perioperative patients who received FLOT chemotherapy

Characteristic	Overall, N=59 ¹	Peri-op chemo, N=37 ¹	TNT, N=22 ¹	P value ²
Age at diagnosis	61 (32, 80)	58 (32, 80)	64 (37, 74)	0.8
Gender				0.1
Male	37 (63%)	26 (70%)	11 (50%)	
Female	22 (37%)	11 (30%)	11 (40%)	
ECOG				0.1
0	35 (59%)	25 (68%)	10 (45%)	
1+	24 (41%)	12 (32%)	12 (55%)	
Primary site				0.2
Upper (Cardia/Fundus)	17 (29%)	8 (22%)	9 (41%)	
Middle (Body)	17 (29%)	13 (35%)	4 (18%)	
Lower (Antrum/Pylorus)	25 (42%)	16 (43%)	9 (41%)	
Clinical T stage ³				0.2
cT1	1 (2.3%)	0 (0%)	1 (6.7%)	
cT2	1 (2.3%)	0 (0%)	1 (6.7%)	
cT3	22 (50%)	15 (52%)	11 (47%)	
cT4	20 (45%)	14 (48%)	6 (40%)	
Unknown	15	8	7	
Clinical N stage				0.13
cN-	23 (40%)	17 (47%)	6 (27%)	
cN+	35 (60%)	19 (53%)	16 (73%)	
Unknown	1	1	0	
Clinical stage group				0.04
IIA	2 (4.7%)	0 (0%)	2 (13%)	
IIB	17 (40%)	14 (50%)	3 (20%)	
III	24 (56%)	14 (50%)	10 (67%)	
Unknown	16	9	7	
Histology (Lauren)				0.3
Intestinal	25 (48%)	18 (53%)	7 (39%)	
Diffuse	21 (40%)	13 (38%)	8 (44%)	
Mixed	6 (12%)	3 (8.8%)	3 (17%)	
Unknown	7	3	4	
Histology (WHO)				>0.9
Poorly differentiated	40 (68%)	23 (62%)	17 (77%)	
Moderately differentiated	19 (32%)	14 (38%)	5 (23%)	
Well differentiated	0 (0%)	0 (0%)	0 (0%)	
Surgery type				0.7
Partial gastrectomy	29 (49%)	19 (51%)	10 (45%)	
Total gastrectomy	30 (51%)	18 (49%)	12 (55%)	

¹Median (Range); n (%); ²Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test; ³AJCC (American Joint Committee on Cancer) tumor (T) stage classification, 8th edition.

Table S2 Pathologic and surgical outcomes for TNT and perioperative patients who received FLOT chemotherapy

	Overall, N=59 ¹	Peri-op chemo, N = 37 ¹	TNT, N = 22 ¹	P value ²
Treatment effect	0.50 (0.30-0.75)	0.40 (0.30-0.68)	0.55 (0.28-0.95)	0.50
Unknown	4	2	2	
yp pathological stage ³				0.11
I	9 (15%)	7 (19%)	2 (9.1%)	
II	28 (47%)	19 (51%)	9 (41%)	
III	19 (32%)	11 (30%)	8 (36%)	
IV	0 (0%)	0 (0%)	0 (0%)	
pCR	3 (5.1%)	0 (0%)	3 (14%)	
ypT stage ³				0.002
ypT0	3 (5.1%)	0 (0%)	3 (14%)	
ypT1	8 (14%)	7 (19%)	1 (4.5%)	
ypT2	6 (10%)	2 (5.4%)	4 (18%)	
ypT3	31 (53%)	24 (65%)	7 (32%)	
ypT4	11 (19%)	4 (11%)	7 (32%)	
ypN stage ³				0.6
ypN0	30 (51%)	21 (57%)	9 (41%)	
ypN1	12 (20%)	6 (16%)	6 (27%)	
ypN2	10 (17%)	6 (16%)	4 (18%)	
ypN3	7 (12%)	4 (11%)	3 (14%)	
Margin status				0.4
R0	54 (92%)	35 (95%)	19 (86%)	
R1	5 (8.5%)	2 (5.4%)	3 (14%)	
Time from last chemo to surgery, days	31 (27, 37)	31 (27, 38)	32 (27, 35)	0.8
Post-op length of stay, days	6 (5, 8)	5 (5, 7)	7 (5, 9)	0.14
Surgical morbidity				0.5
Clavien-Dindo 0	34 (58%)	21 (57%)	13 (59%)	
Clavien-Dindo I-II	20 (34%)	14 (38%)	6 (27%)	
Clavien-Dindo III-IV	5 (8.5%)	2 (5.4%)	3 (14%)	

¹Median (IQR); n (%); ²Wilcoxon rank sum test; Fisher's exact test; ³yp post-neoadjuvant therapy pathological stage, based on AJCC tumor, node, metastasis (TNM) classification 8th edition.

Table S3 Characteristics of patients with R1 resection

Patient	Treatment group	Clinical stage	Histology	Preop Chemo	Surgery	Pathologic stage	Adjuvant Chemotherapy	RFS	OS
37yF	Periop	T4aNx	Poorly differentiated with signet ring cells, diffuse type.	EOX x 3 cycles	Entire stomach from GEJ to pylorus grossly thickened. Open total gastrectomy performed, but positive proximal and distal margins. Unable to achieve R0 resection due to extent of disease.	ypT4aN3a, positive proximal and distal margins	None due to prolonged postop recovery and poor response.	Unknown	11 months
53yM	Periop	T4N0	Poorly differentiated with signet ring cells, diffuse type	FLOT x 4 cycles	Open total gastrectomy after proximal staple line revealed treated tumor. Negative frozen proximal margin.	ypT4aN3a, positive distal margin	FLOT x 4 cycles→ CRT for positive margin.	21 months	39 months
67yF	Periop	TxN0 (no obvious full thickness disease on diag lap, but stomach appeared thickened)	Poorly differentiated with signet ring cells, diffuse type.	FLOT x 1, 5FU/docetaxel x 3 cycles (oxaliplatin stopped for toxicity)	Open distal subtotal gastrectomy. Negative frozen proximal and distal margins.	ypT3N1, positive proximal and distal margins	5FU/docetaxel x 4 cycles→ CRT for positive margin	21 months	25 months
65yF	TNT	T4aN0, linitis plastica on diag lap	Poorly differentiated with signet ring cells, diffuse type	FLOT x 8 cycles	Thickened esophagus but normal on EGD. Positive frozen esophageal margin but further esophageal resection not feasible.	ypT4aN1, positive proximal margin	CRT for positive margin	9 months	17 months
58yF	TNT	TxN0, linitis plastica on diag lap	Poorly differentiated with signet ring cells, diffuse type	FLOT x 8 cycles	Total esophagogastrectomy with colonic interposition reconstruction.	ypT4N2, positive esophageal adventitia margin	None	3 months	6 months
67yF	TNT	T3N+	Poorly differentiated with signet ring cells, diffuse type	FLOT x 8 cycles	Open total gastrectomy. Negative frozen proximal margin.	ypT3N1, positive proximal margin with minute foci of carcinoma	CRT for positive margin	Lost to follow up (no recurrence on 12 month scan)	Lost to follow up at 16 months